Climb Bio, Inc. · NASDAQ:CLYM
Climb Bio — Eliem Therapeutics — Merger or Acquisition (April 2024)
18 slides from Climb Bio's merger presentation, Apr 11, 2024
Slide 1: Tenet Acquisition Overview
TENET ACQUISITION OVERVIEW POTENTIAL FOR BEST-IN-CLASS THERAPIES TO TREAT AUTOANTIBODY-MEDIATED DISEASES April 11, 2024 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and various remarks we make during this presentation contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospec
Slide 3: No Offer or Solicitation
No Offer or Solicitation This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed acquisition and shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall t
Slide 4: Acquisition Overview
Acquisition Overview Eliem Therapeutics to acquire Tenet Medicines in all stock transaction Equityholders of Eliem are expected to own approximately 85% and the former equityholders of Tenet are expected to own approximately 15% of the combined company In support of the acquisition, Eliem has entere
Slide 5: Executive Summary
01 02 03 04 Pipeline Overview & Rationale Competitive Landscape & Differentiation Clinical Proof-of-Concept with TNT119 Future Planning & Outlook Executive Summary
Slide 6: TNT119: Anti-CD19 mAb Designed to Treat Autoantibody-Mediated Diseases
Additional potentially addressable indications across several therapeutic areas Aiming to advance potentially best-in-class mAb to late-stage clinical trial(s) TNT119: Anti-CD19 mAb Designed to Treat Autoantibody-Mediated Diseases Clinical-stage program with potential as a platform molecule for auto
Slide 7: CD19 Expression on Autoantibody-Secreting Cells (ASCs)
Pro-B Pre-B Immature B Naïve B GC B Memory B Plasma blast Plasma cell AAb- secreting B-cells TNT119 CD19 rituximab CD20 CD38 CD22 BAFF-R BCMA TACI CD19 Expression on Autoantibody-Secreting Cells (ASCs) CD19-targeted therapy can potentially deplete a broader B-cell lineage, including AAb-secreting ce
Slide 8: Depletion of CD19-Expressing Plasmablasts and Plasma Cells May Improve Clinical Benefit in Lupus
We Hypothesize That Depletion of CD19-Expressing Plasmablasts and Plasma Cells Can Potentially Lead to Improved Clinical Benefit in Lupus ^Clinical Response Anti-CD20 mAb1 Anti-BAFF mAb2 Anti-CD19 mAb† HIGH LOW efficacy threshold for new therapies †Clinical trials of anti-CD19 mAbs in SLE have not y
Slide 9: ADCC-Enhanced Anti-CD19 mAb Competitive Landscape
ADCC-Enhanced Anti-CD19 mAb Competitive Landscape TNT119 development focused on SLE, MN, and ITP ADCC = antibody-dependent cellular cytotoxicity, mAb = monoclonal antibody, IV = intravenous, SC = subcutaneous Q3M = once every three months, Q6M = once very 6 months, Q1W = once weekly, Q2W = once ever
Slide 10: TNT119 Early Clinical Profile in Membranous Nephropathy
TNT119 Early Clinical Profile in Membranous Nephropathy Preliminary Phase 1b data from evaluable MN patients with ≥48-week follow up†* Phase 1b Dose Escalation Scheme 100 mg TNT119 200 mg TNT119 0 72 24 = TNT119 dose 48 week Cohort 2 Cohort 1 Patients diagnosed with primary MN Complete remission ach
Slide 11: TNT119 Early Clinical Profile in Membranous Nephropathy
TNT119 Early Clinical Profile in Membranous Nephropathy Preliminary Phase 1b data from evaluable MN patients with ≥48-week follow up†* †Three additional MN subjects were dosed with TNT119, however they did not receive all 4 doses and did not reach the 48-week timepoint. *Preliminary data as of 01/23
Slide 12: Prior Studies of CD19-Directed CAR-T Showed Profound Impact in SLE
EFFICACY Multiple case studies demonstrate CD19-directed CAR-T achieved meaningful reductions in symptoms and biomarkers of SLE1 SAFETY Potential risk for T-cell malignancy CRS and/or neurotoxicity can occur Cyclophosphamide conditioning may increase risk of bladder cancer and risk of sterility TOLE
Slide 13: Projected Outlook
Program 2024 2Q24 TNT119 Anti-CD19 Fc+, mAb Q1 Q2 Q3 Q4 Projected Outlook We expect that our cash position following closing of the acquisition and private placement will provide runway into 2027, potentially supporting key clinical readouts for TNT119 SLE P2 OPEN MN P1b ADDITIONAL DATA SC FINAL FOR
Slide 14: Opportunities Across Multiple Patient Populations
Lead Indications Orphan Indications Large Indications Opportunities Across Multiple Patient Populations Significant unmet needs across lead indications, >2.5M US patients with AAb-mediated disease SLE = Systemic Lupus Erythematosus, MN = Membranous Nephropathy, ITP = Immune Thrombocytopenia NMOSD =
Slide 15: Slide 15
Slide 16: Risk Factors
The list below of risk factors has been prepared solely for purposes of the proposed private placement as part of the proposed acquisition between Eliem and Tenet, and solely for potential investors in the private placement, and not for any other purpose. The risks presented below are certain of the
Slide 17: Risks Related to the Proposed Combined Company
Risks Related to the Proposed Combined Company The combined company will incur net losses for the foreseeable future and may never achieve or maintain profitability. The combined company will need additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this n
Slide 18: Eliem Tx / Tenet Medicines Acquisition Update Conference Call Script
Eliem Tx / Tenet Medicines Acquisition Update Conference Call Script April 11, 2024 pg. 1 OPERATOR: Good morning, and welcome to the Eliem Therapeutics and Tenet Medicines Merger webcast and conference call. At this time, all participants are in a listen-only mode. Please be advised that this audio
Eliem Therapeutics — Merger or Acquisition (April 2024) on 6ix